help button home button Endocrine Society Endocrine Reviews
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints, Permissions and Rights
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hofland, L. J.
Right arrow Articles by Lamberts, S. W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hofland, L. J.
Right arrow Articles by Lamberts, S. W. J.
Endocrine Reviews 24 (1): 28-47
Copyright © 2003 by The Endocrine Society

The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance

Leo J. Hofland and Steven W. J. Lamberts

Department of Internal Medicine, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands

Somatostatin receptors expressed on tumor cells form the rationale for somatostatin analog treatment of patients with somatostatin receptor-positive neuroendocrine tumors. Nevertheless, although somatostatin analogs effectively control hormonal hypersecretion by GH-secreting pituitary adenomas, islet cell tumors, and carcinoid tumors, significant differences are observed among patients with respect to the efficacy of treatment. This may be related to a differential expression of somatostatin receptor subtypes among tumors. In addition, the property of somatostatin receptor subtypes to undergo agonist-induced internalization has important consequences for visualizing, as well as for therapy, of receptor-postive tumors using radioisotope- or chemotherapeutic-compound-coupled somatostatin analogs. This review covers the pathophysiological role of somatostatin receptor subtypes in determining the efficacy of treatment of patients with somatostatin receptor-positive tumors using somatostatin analogs, as well as the preclinical and clinical consequences of agonist-induced receptor internalization for somatostatin receptor-targeted radio- and chemotherapy. Herein, the development and potential role of novel somatostatin analogs is discussed.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
C. G. Ziegler, J. W. Brown, A. V. Schally, A. Erler, L. Gebauer, A. Treszl, L. Young, L. M. Fishman, J. B. Engel, H. S. Willenberg, et al.
Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: Antiproliferative effects of peptide analogues
PNAS, September 15, 2009; 106(37): 15879 - 15884.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. Giustina, S. Bonadonna, G. Bugari, A. Colao, R. Cozzi, S. Cannavo, L. de Marinis, E. degli Uberti, F. Bogazzi, G. Mazziotti, et al.
High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial
Eur. J. Endocrinol., August 1, 2009; 161(2): 331 - 338.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
D. Ferone, F. Gatto, M. Arvigo, E. Resmini, M. Boschetti, C. Teti, D. Esposito, and F. Minuto
The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology
J. Mol. Endocrinol., May 1, 2009; 42(5): 361 - 370.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. de Bruin, A. M. Pereira, R. A. Feelders, J. A. Romijn, F. Roelfsema, D. M. Sprij-Mooij, M. O. van Aken, A.-J. van der Lelij, W. W. de Herder, S. W. J. Lamberts, et al.
Coexpression of Dopamine and Somatostatin Receptor Subtypes in Corticotroph Adenomas
J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1118 - 1124.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. Grant, H. Alturaihi, P. Jaquet, B. Collier, and U. Kumar
Cell Growth Inhibition and Functioning of Human Somatostatin Receptor Type 2 Are Modulated by Receptor Heterodimerization
Mol. Endocrinol., October 1, 2008; 22(10): 2278 - 2292.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
N. Kimura, N. Takamatsu, Y. Yaoita, R Y. Osamura, and N. Kimura
Identification of transcriptional regulatory elements in the human somatostatin receptor sst2 promoter and regions including estrogen response element half-site for estrogen activation
J. Mol. Endocrinol., February 1, 2008; 40(2): 75 - 91.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
N. Sharif, L. Gendron, J. Wowchuk, P. Sarret, J. Mazella, A. Beaudet, and T. Stroh
Coexpression of Somatostatin Receptor Subtype 5 Affects Internalization and Trafficking of Somatostatin Receptor Subtype 2
Endocrinology, May 1, 2007; 148(5): 2095 - 2105.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
G. Tulipano and S. Schulz
Novel insights in somatostatin receptor physiology
Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S3 - S11.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
D. Ferone, A. Saveanu, M. D Culler, M. Arvigo, A. Rebora, F. Gatto, F. Minuto, and P. Jaquet
Novel chimeric somatostatin analogs: facts and perspectives
Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S23 - S28.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
J. van der Hoek, S. W J Lamberts, and L. J Hofland
Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas
Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S45 - S51.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
C. Armani, E. Catalani, A. Balbarini, P. Bagnoli, and D. Cervia
Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages
J. Leukoc. Biol., March 1, 2007; 81(3): 845 - 855.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Pivonello, D. Ferone, W. W. de Herder, A. Faggiano, L. Bodei, R. R. de Krijger, G. Lombardi, A. Colao, S. W. J. Lamberts, and L. J. Hofland
Dopamine Receptor Expression and Function in Corticotroph Ectopic Tumors
J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 65 - 69.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Duran-Prado, C. Bucharles, B. J. Gonzalez, R. Vazquez-Martinez, A. J. Martinez-Fuentes, S. Garcia-Navarro, S. J. Rhodes, H. Vaudry, M. M. Malagon, and J. P. Castano
Porcine Somatostatin Receptor 2 Displays Typical Pharmacological sst2 Features but Unique Dynamics of Homodimerization and Internalization
Endocrinology, January 1, 2007; 148(1): 411 - 421.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
D. O'Toole, A. Saveanu, A. Couvelard, G. Gunz, A. Enjalbert, P. Jaquet, P. Ruszniewski, and A. Barlier
The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies
Eur. J. Endocrinol., December 1, 2006; 155(6): 849 - 857.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C Susini and L Buscail
Rationale for the use of somatostatin analogs as antitumor agents
Ann. Onc., December 1, 2006; 17(12): 1733 - 1742.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Ginj, H. Zhang, B. Waser, R. Cescato, D. Wild, X. Wang, J. Erchegyi, J. Rivier, H. R. Macke, and J. C. Reubi
Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors
PNAS, October 31, 2006; 103(44): 16436 - 16441.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
L. Bodei, G. Paganelli, and G. Mariani
Receptor Radionuclide Therapy of Tumors: A Road from Basic Research to Clinical Applications
J. Nucl. Med., March 1, 2006; 47(3): 375 - 377.
[Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
E Thodou, G Kontogeorgos, D Theodossiou, and M Pateraki
Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas.
J. Clin. Pathol., March 1, 2006; 59(3): 274 - 279.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. van der Hoek, M. Waaijers, P. M. van Koetsveld, D. Sprij-Mooij, R. A. Feelders, H. A. Schmid, P. Schoeffter, D. Hoyer, D. Cervia, J. E. Taylor, et al.
Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells
Am J Physiol Endocrinol Metab, August 1, 2005; 289(2): E278 - E287.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
P Jaquet, G Gunz, A Saveanu, H Dufour, J Taylor, J Dong, S Kim, J-P Moreau, A Enjalbert, and M D Culler
Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy
Eur. J. Endocrinol., July 1, 2005; 153(1): 135 - 141.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Melmed, R. Sternberg, D. Cook, A. Klibanski, P. Chanson, V. Bonert, M. L. Vance, D. Rhew, D. Kleinberg, and A. Barkan
A Critical Analysis of Pituitary Tumor Shrinkage during Primary Medical Therapy in Acromegaly
J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4405 - 4410.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
B. Astruc, P. Marbach, H. Bouterfa, C. Denot, M. Safari, A. Vitaliti, and M. Sheppard
Long-Acting Octreotide and Prolonged-Release Lanreotide Formulations Have Different Pharmacokinetic Profiles
J. Clin. Pharmacol., July 1, 2005; 45(7): 836 - 844.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
Q. Liu, R. Cescato, D. A. Dewi, J. Rivier, J.-C. Reubi, and A. Schonbrunn
Receptor Signaling and Endocytosis Are Differentially Regulated by Somatostatin Analogs
Mol. Pharmacol., July 1, 2005; 68(1): 90 - 101.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
D. Vezzosi, A. Bennet, P. Rochaix, F. Courbon, J. Selves, B. Pradere, L. Buscail, C. Susini, and P. Caron
Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies
Eur. J. Endocrinol., May 1, 2005; 152(5): 757 - 767.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
L. J. Hofland, A. Capello, E. P. Krenning, M. de Jong, and M. P. van Hagen
Induction of Apoptosis with Hybrids of Arg-Gly-Asp Molecules and Peptides and Antimitotic Effects of Hybrids of Cytostatic Drugs and Peptides
J. Nucl. Med., January 1, 2005; 46(1_suppl): 191S - 198S.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
G. A. Kaltsas, G. M. Besser, and A. B. Grossman
The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors
Endocr. Rev., June 1, 2004; 25(3): 458 - 511.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Tulipano, R. Stumm, M. Pfeiffer, H.-J. Kreienkamp, V. Hollt, and S. Schulz
Differential {beta}-Arrestin Trafficking and Endosomal Sorting of Somatostatin Receptor Subtypes
J. Biol. Chem., May 14, 2004; 279(20): 21374 - 21382.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. Pacak, I. Ilias, C. C. Chen, J. A. Carrasquillo, M. Whatley, and L. K. Nieman
The Role of [18F]Fluorodeoxyglucose Positron Emission Tomography and [111In]-Diethylenetriaminepentaacetate-D-Phe-Pentetreotide Scintigraphy in the Localization of Ectopic Adrenocorticotropin-Secreting Tumors Causing Cushing's Syndrome
J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2214 - 2221.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. C. Fruhwald, C. H. Rickert, M. S. O'Dorisio, M. Madsen, M. Warmuth-Metz, G. Khanna, W. Paulus, J. Kuhl, H. Jurgens, P. Schneider, et al.
Somatostatin Receptor Subtype 2 Is Expressed by Supratentorial Primitive Neuroectodermal Tumors of Childhood and Can Be Targeted for Somatostatin Receptor Imaging
Clin. Cancer Res., May 1, 2004; 10(9): 2997 - 3006.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. van der Hoek, W. W. de Herder, R. A. Feelders, A.-J. van der Lely, P. Uitterlinden, V. Boerlin, C. Bruns, K. W. Poon, I. Lewis, G. Weckbecker, et al.
A Single-Dose Comparison of the Acute Effects between the New Somatostatin Analog SOM230 and Octreotide in Acromegalic Patients
J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 638 - 645.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Q. Liu, J.-C. Reubi, Y. Wang, B. J. Knoll, and A. Schonbrunn
In Vivo Phosphorylation of the Somatostatin 2A Receptor in Human Tumors
J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 6073 - 6079.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2003 by The Endocrine Society